Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation.

Swaminathan S, Qiu J, Rupert AW, Hu Z, Higgins J, Dewar RL, Stevens R, Rehm CA, Metcalf JA, Sherman BT, Baseler MW, Lane HC, Imamichi T.

PLoS One. 2016 Nov 23;11(11):e0167091. doi: 10.1371/journal.pone.0167091. eCollection 2016.

2.

Circulating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines.

Matsui K, Adelsberger JW, Kemp TJ, Baseler MW, Ledgerwood JE, Pinto LA.

PLoS One. 2015 Sep 2;10(9):e0137195. doi: 10.1371/journal.pone.0137195. eCollection 2015.

3.

Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection.

Swaminathan S, Hu Z, Rupert AW, Higgins JM, Dewar RL, Stevens R, Chen Q, Rehm CA, Metcalf JA, Baseler MW, Lane HC, Imamichi T.

PLoS One. 2014 Jun 4;9(6):e98989. doi: 10.1371/journal.pone.0098989. eCollection 2014.

4.

Interleukin-2 inhibits HIV-1 replication in some human T cell lymphotrophic virus-1-infected cell lines via the induction and incorporation of APOBEC3G into the virion.

Oguariri RM, Dai L, Adelsberger JW, Rupert A, Stevens R, Yang J, Huang D, Lempicki RA, Zhou M, Baseler MW, Lane HC, Imamichi T.

J Biol Chem. 2013 Jun 14;288(24):17812-22. doi: 10.1074/jbc.M113.468975. Epub 2013 May 2.

5.

Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties.

Swaminathan S, Hu X, Zheng X, Kriga Y, Shetty J, Zhao Y, Stephens R, Tran B, Baseler MW, Yang J, Lempicki RA, Huang D, Lane HC, Imamichi T.

Biochem Biophys Res Commun. 2013 May 3;434(2):228-34. doi: 10.1016/j.bbrc.2013.03.046. Epub 2013 Mar 25.

6.

The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls.

Imamichi H, Lempicki RA, Adelsberger JW, Hasley RB, Rosenberg A, Roby G, Rehm CA, Nelson A, Krishnan S, Pavlick M, Woods CJ, Baseler MW, Lane HC.

Eur J Immunol. 2012 Oct;42(10):2608-20. doi: 10.1002/eji.201142046. Epub 2012 Aug 6.

7.

DAVID-WS: a stateful web service to facilitate gene/protein list analysis.

Jiao X, Sherman BT, Huang da W, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Bioinformatics. 2012 Jul 1;28(13):1805-6. doi: 10.1093/bioinformatics/bts251. Epub 2012 Apr 27.

8.

Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN.

Zhang X, Brann TW, Zhou M, Yang J, Oguariri RM, Lidie KB, Imamichi H, Huang DW, Lempicki RA, Baseler MW, Veenstra TD, Young HA, Lane HC, Imamichi T.

J Immunol. 2011 Apr 15;186(8):4541-5. doi: 10.4049/jimmunol.1003389. Epub 2011 Mar 11.

9.

Evaluation of the effect of pyrimethamine, an anti-malarial drug, on HIV-1 replication.

Oguariri RM, Adelsberger JW, Baseler MW, Imamichi T.

Virus Res. 2010 Nov;153(2):269-76. doi: 10.1016/j.virusres.2010.08.018. Epub 2010 Aug 26.

10.

DAVID gene ID conversion tool.

Huang da W, Sherman BT, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Bioinformation. 2008 Jul 30;2(10):428-30.

11.

Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SB, Kovacs JA, Davey RT, Lane HC, Masur H, Sereti I.

Blood. 2008 Jul 15;112(2):287-94. doi: 10.1182/blood-2007-12-127878. Epub 2008 May 2. Erratum in: Blood. 2014 Jul 17;124(3):463. Kovacs, Stephen J [corrected to Kovacs, Stephen B].

12.

IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages.

Imamichi T, Yang J, Huang DW, Brann TW, Fullmer BA, Adelsberger JW, Lempicki RA, Baseler MW, Lane HC.

AIDS. 2008 Jan 2;22(1):39-45.

PMID:
18090390
13.

DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis.

Sherman BT, Huang da W, Tan Q, Guo Y, Bour S, Liu D, Stephens R, Baseler MW, Lane HC, Lempicki RA.

BMC Bioinformatics. 2007 Nov 2;8:426.

14.

The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists.

Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Genome Biol. 2007;8(9):R183.

15.

Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection.

Pascal V, Yamada E, Martin MP, Alter G, Altfeld M, Metcalf JA, Baseler MW, Adelsberger JW, Carrington M, Anderson SK, McVicar DW.

J Immunol. 2007 Aug 1;179(3):1625-33.

16.

DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists.

Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA.

Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75. Epub 2007 Jun 18.

17.

Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT Jr, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Issaq HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC.

J Clin Invest. 2005 Aug;115(8):2139-48. Epub 2005 Jul 14.

18.

A comparison of microLC/electrospray ionization-MS and GC/MS for the measurement of stable isotope enrichment from a [2H2]-glucose metabolic probe in T-cell genomic DNA.

Fox SD, Lempicki RA, Hosack DA, Baseler MW, Kovacs JA, Lane HC, Veenstra TD, Issaq HJ.

Anal Chem. 2003 Dec 1;75(23):6517-22.

PMID:
14640722
19.

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.

Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A.

J Infect Dis. 2003 Jul 15;188(2):327-38. Epub 2003 Jul 9.

PMID:
12854090
20.

Actinomycin D induces high-level resistance to thymidine analogs in replication of human immunodeficiency virus type 1 by interfering with host cell thymidine kinase expression.

Imamichi T, Murphy MA, Adelsberger JW, Yang J, Watkins CM, Berg SC, Baseler MW, Lempicki RA, Guo J, Levin JG, Lane HC.

J Virol. 2003 Jan;77(2):1011-20.

21.

Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells.

Sereti I, Martinez-Wilson H, Metcalf JA, Baseler MW, Hallahan CW, Hahn B, Hengel RL, Davey RT, Kovacs JA, Lane HC.

Blood. 2002 Sep 15;100(6):2159-67.

22.

Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection.

Natarajan V, Lempicki RA, Sereti I, Badralmaa Y, Adelsberger JW, Metcalf JA, Prieto DA, Stevens R, Baseler MW, Kovacs JA, Lane HC.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10712-7. Epub 2002 Jul 29.

23.

Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, Falloon J, Stevens R, Lambert L, Dewar R, Schwartzentruber DJ, Anver MR, Baseler MW, Masur H, Dimitrov DS, Lane HC.

J Exp Med. 2001 Dec 17;194(12):1731-41.

24.

Evidence for increased T cell turnover and decreased thymic output in HIV infection.

Douek DC, Betts MR, Hill BJ, Little SJ, Lempicki R, Metcalf JA, Casazza J, Yoder C, Adelsberger JW, Stevens RA, Baseler MW, Keiser P, Richman DD, Davey RT, Koup RA.

J Immunol. 2001 Dec 1;167(11):6663-8.

25.

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients.

Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT, Lane HC.

AIDS. 2001 Sep 28;15(14):1765-75.

PMID:
11579237
26.

Correlation of human CD56+ cell cytotoxicity and IFN-gamma production.

Derby EG, Reddy V, Nelson EL, Kopp WC, Baseler MW, Dawson JR, Malyguine AM.

Cytokine. 2001 Jan 21;13(2):85-90.

PMID:
11145847
27.

Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.

Lempicki RA, Kovacs JA, Baseler MW, Adelsberger JW, Dewar RL, Natarajan V, Bosche MC, Metcalf JA, Stevens RA, Lambert LA, Alvord WG, Polis MA, Davey RT, Dimitrov DS, Lane HC.

Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13778-83.

28.
29.

Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease.

Koenig S, Woods RM, Brewah YA, Newell AJ, Jones GM, Boone E, Adelsberger JW, Baseler MW, Robinson SM, Jacobson S.

J Immunol. 1993 Oct 1;151(7):3874-83.

PMID:
7690819
30.

Immunological monitoring and clinical trials of biological response modifiers.

Baseler MW, Kopp WC, Urba WJ.

Cancer Chemother Biol Response Modif. 1993;14:249-83. Review. No abstract available.

PMID:
7508729
31.

Immunological monitoring and clinical trials of biological response modifiers.

Baseler MW, Urba WJ.

Cancer Chemother Biol Response Modif. 1992;13:205-29. Review. No abstract available.

PMID:
1382527
32.

Immunological monitoring and clinical trials of biological response modifiers.

Baseler MW, Urba WJ.

Cancer Chemother Biol Response Modif. 1991;12:231-50. Review. No abstract available.

PMID:
1931445
34.

Immunological monitoring and clinical trials of biological response modifiers.

Urba WJ, Baseler MW.

Cancer Chemother Biol Response Modif. 1990;11:281-302. Review. No abstract available.

PMID:
2121208
35.

Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial.

Lane HC, Falloon J, Walker RE, Deyton L, Kovacs JA, Masur H, Banks S, Kirk LE, Baseler MW, Salzman NP, et al.

Ann Intern Med. 1989 Jul 1;111(1):41-50. Erratum in: Ann Intern Med 1990 Mar 1;112(5):388.

PMID:
2735626
36.

Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.

Urba WJ, Baseler MW, Kopp WC, Steis RG, Clark JW, Smith JW 2nd, Coggin DL, Longo DL.

Blood. 1989 Jan;73(1):38-46.

37.

Immunological monitoring and clinical trials of biological response modifiers.

Urba WJ, Baseler MW.

Cancer Chemother Biol Response Modif. 1988;10:473-91. Review. No abstract available.

PMID:
2484322
38.
39.

A new class of synthetic biological response modifiers: the methylfurylbutyrolactones (Nafocare B).

Veltri RW, Fodor G, Liu CM, Woolverton CJ, Baseler MW.

J Biol Response Mod. 1986 Oct;5(5):444-61.

PMID:
3021912
40.

Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck.

Veltri RW, Rodman SM, Maxim PE, Baseler MW, Sprinkle PM.

Cancer. 1986 Jun 15;57(12):2295-308.

PMID:
3084060
41.

Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responses.

Baseler MW, Burrell R.

Inflammation. 1983 Dec;7(4):387-400.

PMID:
6654476
42.

Differential toxicity of inhaled gram-negative bacteria.

Baseler MW, Fogelmark B, Burrell R.

Infect Immun. 1983 Apr;40(1):133-8.

43.

Acute-phase reactants in experimental inhalation lung disease.

Baseler MW, Burrell R.

Proc Soc Exp Biol Med. 1981 Oct;168(1):49-55.

PMID:
7323066

Supplemental Content

Loading ...
Support Center